For treatment with EGFR inhibitors, METamp has been established as a mechanism of acquired resistance, and evidence is accumulating that this could also occur in NSCLC with targeted therapies related to ALK-, RET-, and ROS1-rearrangements. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.